Personalis Inc (PSNL) Stock Analysis
Verdict: AVOID
Personalis trades at a steep 25.7x P/S premium despite negative revenue growth (-13.3%) and gross margins of 12.7% trailing peer averages.
Investment score: 33/100
Analysis as of
Is Personalis Inc stock worth reviewing? AI model thesis
The AI model rates Personalis Inc (PSNL) as AVOID due to a rich valuation (25.71x P/S) coupled with contracting revenue (-13.26%), low gross margins (12.69%), heavy annual cash burn (-79.45M USD), and insider selling.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Personalis Inc opportunities and risks
What speaks for PSNL
- Expansion of NeXT Personal liquid biopsy adoption in clinical oncology trials
What speaks against PSNL
- Severe gross margin weakness relative to sector peer group
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PSNL | n/a | 25.7x | n/a | 12.7% | -153.8% | -5.6% |
| ADPT | n/a | 12.9x | n/a | 75.4% | -20.7% | -0.6% |
| ALMR | n/a | 38.2x | n/a | 58.0% | -62.2% | -1.7% |
| MRVI | n/a | 10.1x | n/a | 34.6% | -37.1% | -1.7% |
| BLFS | 35.9x | 17.6x | 184.3x | 64.5% | 49.1% | -0.0% |
| Peer median | n/a | 15.3x | n/a | 61.2% | -28.9% | -1.1% |
Frequently asked questions about Personalis Inc (PSNL)
Is PSNL stock a good investment?
The cached TradeMates AI model rates Personalis Inc as AVOID with an investment score of 33/100. The AI model rates Personalis Inc (PSNL) as AVOID due to a rich valuation (25.71x P/S) coupled with contracting revenue (-13.26%), low gross margins (12.69%), heavy annual cash burn (-79.45M USD), and insider selling. This is algorithmic model output, not personal investment advice.
Is PSNL stock a buy?
The TradeMates model verdict for PSNL is AVOID with an investment score of 33/100. Treat this as a model signal to review, not a personal buy recommendation.